Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Protein Design Labs

Executive Summary

MSL-109 Phase I/II trial results indicate the anti-cytomegalovirus antibody in combination with ganciclovir or foscarnet may delay progression to CMV retinitis at least twice as long as either drug alone. The data on 17 AIDS patients, presented June 10 at the Ninth International Conference on AIDS in Berlin, show that median delay in progression to CMV retinitis was 202 days compared to 60-100 days for ganciclovir or foscarnet in other studies. Protein Design Labs is planning to begin a Phase II/III trial of MSL-109 in CMV retinitis next year.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022792

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel